Vellykket registrering
Din registrering er satt på vent
Din konto er aktivert, men fordi vårt system ikke umiddlebart kunne gjenkjenne deg som helsepersonell må det gjøres en manuell sjekk. Du vil motta en e-post med resulatet i løpet av få dager.
I mellomtiden har du tilgang til alle tjenester på portalen.
Severe Asthma (SA) with eosinophilic phenotype
Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.1
Nucala has been on the market for more than 10 years.1
Since March 2016 Nucala has been approved as an add-on treatment for SA (severe asthma with an eosinophilic phenotype) in adults, adolescents and children aged 6 years and older. In November 2021, Nucala was also approved for three additional indications: CRSwNP (chronic rhinosinusitis with nasal polyps), EGPA (eosinophilic granulomatosis with polyangiitis) and HES (hypereosinophilic syndrome).
Since February 2026 Nucala has also been approved as an add-on maintenance treatment for uncontrolled COPD (chronic obstructive pulmonary disease).1
For relevant scientific information on each indication, click on the button.
Nucala (mepolizumab, 100 mg, 40 mg) for subcutaneous injection once every 4 weeks (pre‑filled pen 100 mg, pre‑filled syringe 40 mg and 100 mg) is indicated in:
COPD (Chronic Obstructive Pulmonary Disease) as an add-on maintenance treatment for uncontrolled COPD characterised by elevated blood eosinophils, in combination with an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA).
Severe asthma (SA), as add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), as add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
Eosinophilic Granulomatosis with polyangiitis (EGPA), as add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis.
Hypereosinophilic Syndrome (HES), as add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without any identifiable non-haematologic secondary cause.
SELECTED SAFETY INFORMATION
Warnings and precautions:
Should not be used to treat acute asthma or COPD exacerbations. Patients should be advised to seek medical attention if asthma or COPD remains uncontrolled or worsens after initiation of treatment. Abrupt discontinuation of corticosteroids after starting treatment is not recommended.
Allergic reactions:-
Acute and delayed systemic reactions, including hypersensitivity reactions, have been reported. Patients should be advised to seek immediate medical attention if allergic reactions occur. Appropriate treatment should be initiated in case of hypersensitivity reactions.
Parasitic infections:-
Pre-existing helminth infections should be treated prior to initiation of treatment. If patients become infected during Nucala treatment and do not respond to anti-helminth treatment, temporary discontinuation of Nucala should be considered.
COPD patients with low blood eosinophil count:-
Data do not support use in COPD patients with a blood eosinophil count <150 cells/µL and no evidence of eosinophil counts ≥300 cells/µL within the past 12 months.
Organ-threatening or life-threatening manifestations of EGPA and HES:-
Have not been studied.
Adverse reactions:
In clinical studies in patients with severe refractory eosinophilic asthma and EGPA, the most commonly reported adverse reactions during treatment were headache, injection site reactions, and back pain.
In patients with COPD:- headache, back pain, and arthralgia.
In patients with CRSwNP:- headache and back pain. In patients with HES:- headache, urinary tract infection, injection site reactions, and pyrexia.
Reseptgruppe C.
Finansiering: H-resept: R03D X09_1 Mepolizumab.
Der det er utarbeidet nasjonale handlingsprogrammer/nasjonal faglig retningslinje og/eller anbefalinger fra RHF/LIS spesialistgruppe skal rekvirering gjøres i tråd med disse. Vilkår: 216 Refusjon ytes kun etter resept fra sykehuslege eller avtalespesialist.
Maksimalpriser: 100 mg 1 stk ferdigfylt penn/sprøyte 13587,10 kr. 40 mg 1 stk ferdigfylt sprøyte 5537,80 kr.
Avtalepris inngår i Sykehusinnkjøp anbud Alvorlig ukontrollert T2-høy astma fra 01.09.2024. Anbudet inneholder rabatterte priser.Nucala (mepolizumab) er besluttet innført av Beslutningsforum til behandling av alvorlig eosinofil astma, kronisk rhinosinusitt med nasal polypose (CRSwNP) og hypereosinofilt syndrom (HES). Det er besluttet at Nucala ikke skal benyttes til granulomatose med polyangiitt (EGPA). Nucala er per i dag ikke finansiert for pasienter med kols.
Adverse events should be reported to GlaxoSmithKline on 22 70 20 00. Read the prescribing information before prescribing Nucala.
References
©2026 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies. GlaxoSmithKline AS - Org.nr. 930 606 308 - Drammensveien 288, 0283 Oslo.
PM-NO-MPL-WCNT-260001 June 2026
